*April 2021* During the past decade, evidence has been building that non–small cell lung cancer (NSCLC) has a distinct clinical
*April 2021* Single-agent telisotuzumab vedotin (teliso-v; ABBV-399) induced an encouraging objective response rate (ORR) with a tolerable safety profile in
*April 2021* NOTE: In a small percentage of EGFR+ lung cancer patients, transformation to SCLC can occur, perhaps as a resistance mechanism.
*April 2021* The HER3-directed antibody-drug conjugate patritumab deruxtecan is under exploration in the treatment of patients with EGFR-mutated, metastatic or
*March 2021* Jason Porter, MD, discusses potential sequencing strategies with antibody-drug conjugates and TKIs in HER2-positive lung cancer. Listen here.
*May 2021* The advent of molecular targeted therapies and the more recent introduction of immune checkpoint inhibitors (ICIs) have altered
*March 2021* In this podcast, Benjamin P. Levy, MD, an associate professor of oncology and clinical director of Medical Oncology
*March 2021* Osimertinib (Tagrisso) has demonstrated significant benefit in the frontline metastatic and adjuvant settings in patients with stage IV
*April 2021* Lung cancer expert Dr. Pasi Janne, a professor of medicine at Harvard Medical School and a translational thoracic medical
*March 2021* Want to know more details about our two self-funded EGFR Resisters research projects in partnership with LUNGevity? 1. TARGETING